

The Role of Advanced Glycation End Products in Aging and Metabolic Diseases: Bridging Association and Causality

Jyotiska Chaudhuri,^{1,*} Yasmin Bains,² Sanjib Guha,¹ Arnold Kahn,^{1,3} David Hall,¹ Neelanjana Bose,^{1,3} Alejandro Gugliucci,^{2,*} and Pankaj Kapahi^{1,3,*}

¹The Buck Institute for Research on Aging, 8001 Redwood Boulevard, Novato, CA 94945, USA

²Touro University College of Osteopathic Medicine, Glycation Oxidation and Research laboratory, Vallejo, CA, 94592, USA

³University of California, Department of Urology, 400 Parnassus Avenue, San Francisco, CA 94143, USA

*Correspondence: jchaudhuri@buckinstitute.org (J.C.), alejandrogugliucci@tu.edu (A.G.), pkapahi@buckinstitute.org (P.K.)
<https://doi.org/10.1016/j.cmet.2018.08.014>

Accumulation of advanced glycation end products (AGEs) on nucleotides, lipids, and peptides/proteins are an inevitable component of the aging process in all eukaryotic organisms, including humans. To date, a substantial body of evidence shows that AGEs and their functionally compromised adducts are linked to and perhaps responsible for changes seen during aging and for the development of many age-related morbidities. However, much remains to be learned about the biology of AGE formation, causal nature of these associations, and whether new interventions might be developed that will prevent or reduce the negative impact of AGEs-related damage. To facilitate achieving these latter ends, we show how invertebrate models, notably *Drosophila melanogaster* and *Caenorhabditis elegans*, can be used to explore AGE-related pathways in depth and to identify and assess drugs that will mitigate against the detrimental effects of AGE-adduct development.

Introduction

A heterogeneous group of molecules collectively called advanced glycation end products (AGEs), are produced in the classical Maillard reaction, discovered at the beginning of the 20th century (Maillard, 1912). More than three decades ago, Monnier and Cerami proposed a Maillard theory of aging postulating that slow and continuous accumulation of AGEs was a causal factor in aging (Bjorksten, 1968; Monnier, 1989; Monnier et al., 1988; Sell and Monnier, 1989). Furthermore, they proposed that the protracted buildup of these compounds may alter the structure and function of proteins, thus affecting several of the hallmarks of aging (Gugliucci and Menini, 2017; López-Otín et al., 2013). This process may also contribute to the pathology of metabolic diseases, such as diabetes and atherosclerosis, as well as oxidative stress and inflammation associated with neurodegenerative diseases of aging. Support for this hypothesis includes an age-dependent increase in browning (Maillard reaction), fluorescence, cross-linking, insolubility, and accrual of AGEs in collagens and lens crystallins (Monnier et al., 1984). Despite this accumulating evidence, debate continues over whether AGEs are causal or just a consequence of aging and age-related diseases (Gugliucci, 2017).

The link between age-related diseases and AGEs has been difficult to unravel for several reasons: (1) the variety of sources for AGEs, (2) the gradual buildup of AGEs, which can take decades to detect in humans, (3) lack of accessible and sensitive methods to quantify specific AGEs, (4) a growing number of targets of AGEs, and (5) a lack of models that recapitulate the pathologies resulting from the accumulation of AGEs. These factors have complicated efforts to model causation by connecting an AGE to one specific target and a specific disease relevant to aging.

In this review, we first focus on the chemistry of AGEs, how they accumulate through *in situ* synthesis or via ingestion of food, the naturally occurring mechanisms that reduce their formation, and their metabolism at the whole-body level. We then explore the causative mechanistic links that impact aging and metabolic diseases via accumulation of AGEs. We suggest considerations for developing model systems to study the impact of AGEs. Finally, we illustrate how modeling of AGEs using model organisms, notably worms and flies, can be used to identify “anti-AGE” drugs and examine their relevance to age-related diseases, including diabetic complications and neurodegeneration.

The Maillard Reaction: Initiators, Propagators, and Chemistry

AGEs are produced by glycation in cells or in long-lived extracellular proteins. Protein glycation is a complex series of sequential reactions collectively called the Maillard reaction (Figure 1), present in all tissues and fluids where significant concentration of glucose, fructose, or more reactive dicarbonyls react with proteins (Sell et al., 1992; Monnier et al., 1981). When glucose mediates the reaction, initially the Amadori adduct fructosyllysine is formed. In hemoglobin, this adduct is called HbA1c, which revolutionized the diagnosis and follow-up of diabetic patients (Rahbar et al., 1969). However, HbA1c only assesses glucose-derived products. There is an urgent need to develop markers of AGEs based on downstream products of glucose metabolism like α -dicarbonyl compounds (α -DCs) that are significantly more reactive than glucose and examine their link with various age-related pathologies.

Chronic hyperglycemia results in several metabolic and biochemical perturbations, including elevation of a series of






Figure 1. The Maillard Reaction or Glycation

Main pathways and main known advanced glycation end products (AGEs) relevant to human pathology. In the left column, we represent the main initiators or stressors, propagators in the center (very potent α -dicarbonyls, of which methylglyoxal is the most important and reactive), and end products in the right column. Among the end products: black represents lysine modifications, red indicates arginine adducts, and blue denotes lysine-arginine modifications. CEL, carboxy ethyl lysine; CML, carboxy methyl lysine; MG-H1, methylglyoxal hydroimidazolone; MODIC, methylglyoxal dimer imidazolone crosslink; MOLD, Methylglyoxal lysine dimer; GODIC, glyoxal-derived imidazolium cross-link; DOGDC, 3-deoxyglucosone-derived imidazolium cross-link; GOLD, glyoxal lysine dimer; DOLD, deoxyglucosone lysine dimer. * indicates crosslinked products. Modified from Monnier et al. (2005).

highly reactive α -DCs, such as methylglyoxal (MGO), glyoxal (GO), and 3-deoxyglucosone (3DG) (Henning et al., 2014; Singh et al., 2014). The α -DCs are unavoidable byproducts of anaerobic glycolysis and to a smaller degree lipid peroxidation (Lange et al., 2012; Rabbani and Thornalley, 2014; Thornalley et al., 2003), which react indiscriminately with proteins, lipids, and DNA to yield AGEs (Peppas and Vlassara, 2005; Thornalley et al., 2003). The production of MGO, a key precursor of the AGEs, occurs spontaneously from the triose phosphate isomers glyceraldehyde-3 phosphate and dihydroxyacetone phosphate during glycolysis (Kiefer et al., 2014; Sousa Silva et al., 2013) and is primarily due to β -elimination of a phosphate group from the enediolate phosphate intermediate. The study of the role of α -DCs like MGO in AGEs has lagged due to their unstable nature, which makes them hard to detect in standard metabolomics studies, and because they are non-enzymatic byproducts of metabolic reactions.

Important sources of AGEs include hydroimidazolones derived from arginine residues modified by GO, MGO, and 3-DG, which we will discuss extensively in this review. Other crucial AGEs compounds are N ϵ -carboxymethyl-lysine (CML), N ϵ -carboxyethyl-lysine (CEL), pentosidine, pyrraline, and glucosepane (Nemet et al., 2011; Sveen et al., 2015). As discussed in detail below, the catabolism of cellular AGEs yields a new pool of second generation, highly reactive AGE intermediates (peptides and free adducts) named glycotoxins by some authors (Koschinsky et al., 1997; Uribarri et al., 2003a, 2003b), which pass through the bloodstream to compound cellular damage. Some of these serum AGE-small adducts react with new proteins (e.g., LDL, collagen), perpetuating and propagating oxidative modifications and/or producing new AGE crosslinks *in vitro* and *in vivo* (Gugliucci and Bendayan, 1996; Makita et al., 1994; Vlassara et al., 1992).

AGE formation renders irreversible damage to the biological macromolecules, altering their structural and functional integrity

(Singh et al., 2014). Kinetics of AGE formation through a reaction between MGO and most susceptible amino acids such as arginine, lysine, and cysteine have been studied *in vitro* by incubating bovine serum albumin (BSA) and MGO under physiological conditions (Lo et al., 1994). These studies indicate the irreversible formation of MGO adducts mainly on arginine and lysine. As shown in Figure 1, the adducts primarily result from a reaction between MGO and N α -acetylarginine on the peptide backbone leading to an irreversible imidazolone derivative or hydroimidazolone (MG-H1) through autoxidation of an intermediate 1,5-dihydroimidazolone (Lo et al., 1994). Also, modification of the lysine residues triggered by MGO results in N ϵ -carboxyethyl-lysine (CEL) (Rabbani and Thornalley, 2015a).

In addition to amino acids, specific nucleotides are also susceptible to modification by MGO. DNA-AGEs such as N 2 (1-carboxyethyl)-2'-deoxyguanosine (CEdG) have been described as a potential biomarker of chronic hyperglycemia in mice. CEdG levels are significantly elevated in urine collected from hyperglycemic Lep $^{db/db}$ mice compared to normoglycemic control mice (Jaramillo et al., 2017). Notably, many of the same compounds are produced in baked and roasted foods (Delgado-Andrade and Fogliano, 2018). Administration of dietary AGEs in mice suggests that AGEs consumed through dry-heat-cooked food (Cai et al., 2012; Goldberg et al., 2004) could potentially enhance the risk for age-related diseases (Goldberg et al., 2004), as depicted further below in Figure 4, via activation of the receptor of AGE (RAGE). The biochemistry of AGE formation and its downstream effects are complex and remain to be fully understood. Nevertheless, it is crucial to understand the dicarbonyl detoxification mechanisms that are potential therapeutic targets for AGE-mediated diseases as well as the pathways for the disposal of AGEs after they are generated.

The α -DC Detoxification Network

In the first decade of glycation research, the emphasis was on extracellular glycation of collagens, crystallins, and other long-lived proteins. These proteins are correlated with aging and have been shown to be important in the pathogenesis of diabetic complications. Since then, more attention has been devoted to




Figure 2. Formation of AGEs and the Glyoxalase System

The figure illustrates the formation and detoxification of MGO, a glycolytic byproduct that is formed from either glucose or fructose. Endogenously derived glycolytic byproducts (e.g., Methylglyoxal or MGO) or their AGE derivatives (e.g., N ϵ -carboxyethyl-lysine or CEL and Methylglyoxal-derived hydroimidazolone or MG-H1) lead to a variety of diseases affecting different organs (such as brain, heart, eyes, kidney, lungs) that complicate with age. In addition to endogenous sources such as glucose- or fructose-derived dihydroxyacetone phosphate (DHAP) (formed during glycolysis), exogenous dietary sources such as dry-heated food predominantly produces AGEs (large red arrow). Detoxification of MGO occurs via glutathione (GSH)-dependent glyoxalase pathway mediated by two mitochondrial enzymes glyoxalase I (*GLO1*) and glyoxalase II (*GLO2*) that eventually converts MGO to lactic acid. Alternatively, MGO can also be converted to lactic acid in a single step mediated by a GSH-independent cytosolic enzyme glyoxalase III (*GLO3*), a mammalian ortholog of the protein *DJ1/PARK7*.

intracellular glycation, especially by methylglyoxal, which is between 2 and 3 orders of magnitude more reactive than glucose. The importance of methylglyoxal is underscored by the existence of several conserved enzymes involved in its detoxification.

Glyoxalases such as glyoxalase I (*GLO1*) and *DJ1/PARK7* are an evolutionarily conserved group of enzymes involved in the detoxification of reactive α -DCs including methylglyoxal and glyoxal that eventually get converted into lactic or glycolic acid as depicted in Figure 2. Studies using knockdown of these enzymes in mice, cell culture, and worms show that these genes play a critical role in avoiding pathologies resulting from the accumulation of α -DC-mediated modification of amino acids or nucleotides (Giacco et al., 2014; Lee et al., 2012; Richarme et al., 2017). The tissue specificity and sub-cellular localization of the different glyoxalase enzymes are not well understood. The glyoxalase system can be either glutathione GSH dependent (e.g., *Glo1*) or GSH independent (e.g., *Dj-1*) (Lee et al., 2012; Thornalley, 1990). In recent years, a number of human cohort studies have provided evidence that polymorphisms associated with genes that detoxify α -DCs are linked to certain age-related diseases. Polymorphisms associated with the glyoxalase *Glo1* gene have been associated with the development of nephropathy and retinopathy in type 2 diabetics (Gale et al., 2004; Kalousova et al., 2008; Wu et al., 2011). Genotyping of whole-blood lysates obtained from type 1 and type 2 diabetics revealed a marked decrease in the activity of glyoxalase I that was predicted to be associated to three SNPs (Peculis et al., 2013). In addition to glyoxalase I, variations within the *Dj-1* glyoxalase have also been associated with age-related diseases such as

Parkinson's disease (PD). A study on 294 PD patients in Southern Italy demonstrated the association of sporadic PD with 5 SNPs within the 3,535 bp region extending from the promoter to intron 2 of the *Dj-1* gene (De Marco et al., 2010).

Recent studies in *Escherichia coli* show that the protein *DJ1* possesses deglycase activity that restores proteins and amino acids from glycation events induced by methylglyoxal or glyoxal (Richarme et al., 2015). The deglycase activity of *DJ1* was not supported in a follow-up study due to a potential artifact arising from TRIS buffer (Pfaff et al., 2017). More recent studies using deglycase-depleted cells reinforce *DJ1* as a bona fide deglycase (Richarme and Dairou, 2017). The late stages of the Maillard reaction that form AGEs are considered to be irreversible. However, if the early steps of AGE formation are reversible, then it will provide another step for potential intervention.

Other Detoxifying Enzymes for Dicarbonyls and Early Glycation Adducts

Another class of enzymes that play a critical role in the detoxification of the reactive α -DCs is the evolutionarily conserved NADPH-dependent aldo-keto reductases (AKRs) (Vander Jagt et al., 1992). AGE-mediated atherosclerotic lesion formation was enhanced in the absence of AKRs (Baba et al., 2009). Another mechanism of protection against glycation-mediated damage has been shown via AGE sequestration by lysozymes resulting in improved renal excretion in mice (Zheng et al., 2001). As stated earlier, due to its stability in the closed ring conformation, glucose is not as strong a glycating agent as MGO. However, its effects are important in erythrocytes and other cells that mainly use GLUT I (non-insulin-dependent) transporter. As shown in Figure 1, the early Schiff base formed




Figure 3. AGE Metabolism

The diagram represents schematically the production of endogenous AGEs (intra- and extracellular) and the intake from certain foods (left), their presence in the circulation (center), and their elimination/catabolism mainly by the kidneys (right). AGEs can be produced intracellularly by multiple pathways as shown in Figure 1. Of special relevance are MGO-generated AGEs. Other AGEs are generated on collagens and other proteins in the ECM as we age, and more rapidly during diabetes. Partial proteolysis by macrophages, or in cells by ubiquitin-mediated proteasome pathways, produces partially digested AGE-peptides as well as free adducts. Some AGEs are thought to also enter the bloodstream from foods. These adducts are very reactive and can damage proteins as they transit in the bloodstream. Renal function is critical for their elimination, as end-stage renal failure patients have very high concentrations of these molecules, which can be lowered by dialysis. These AGEs are filtered and reabsorbed in part in the proximal tube to be detoxified to some extent and then secreted distally for urinary excretion.

between glucose and lysine in proteins stabilizes into a fructosamine. Until the last decade, the fate of fructosamines in mammalian cells was only considered to be their spontaneous conversion into AGEs, as shown in Figure 1. A mammalian fructosamine-3-kinase (FN-3-K), which phosphorylates fructoselysine (FL) residues on glycated proteins to FL-3-phosphate, has been isolated and cloned (Delpierre et al., 2004). This unveiled an unsuspected intracellular metabolism of glucose adducts. FN-3-K phosphorylates both low-molecular-mass and protein-bound fructosamines with high affinity for the third carbon of their deoxyfructose moiety, producing fructosamine 3-phosphates. The latter are unstable and spontaneously decompose into inorganic phosphate and 3-deoxyglucosone, regenerating the unglycated amine (Gugliucci, 2005). The presence of proteins related to fructosamine 3-kinase in many prokaryotic and eukaryotic genomes implies that this “deglycation” process is not restricted to erythrocytes or to just mammals (Collard et al., 2004; Dunmore et al., 2018; Van Schaftingen et al., 2007; Szwegold et al., 2011).

A schematic describing some of the known steps in the formation and detoxification of AGEs is shown in Figure 2. Potentially, several regulators of glyoxalases and alpha keto-reductases, in addition to other enzymes that can detoxify AGEs, exist and remain to be discovered. Therefore, in addition to our existing body of knowledge on the detoxification pathways, there is a need for studies using model systems that are amenable to large genetic screens, such as worms, flies, and yeast, to determine

additional genes and their regulators in the α -dicarbonyl detoxification network. These studies are likely to be pivotal in providing new drug targets that limit the accumulation of AGEs that build up with age.

Systemic Metabolism and Handling of AGEs, the Key Role of the Kidney

AGEs are produced endogenously but are also consumed through the diet, especially through dry-heat-cooked food. Human serum contains partially hydrolyzed AGE peptides and free AGE adducts (Bucala et al., 1994; Gugliucci and Bendayan, 1996). These are increased in diabetes and more so in end-stage renal failure even in the absence of diabetes. In earlier studies, we presented the renal fate of AGEs (Gugliucci and Bendayan 1995, 1996) and have shown that AGE peptides are filtered and then reabsorbed in the proximal tubules followed by excretion of free AGE adducts, as depicted in Figure 3. To determine this fate, AGE-BSA and AGE-peptides were injected in rats, and AGE-products in renal tissue of rats were monitored by colloidal gold post-embedding immunoelectron microscopy (Gugliucci and Bendayan 1995, 1996). We showed that the endo-lysosomal apparatus of the proximal convoluted tubule plays a role in the disposal of AGE-peptides. AGE-peptide clearance in humans and rats is lower than the creatinine clearance, which suggests that not all of circulating AGE-peptides are secreted in the urine; reabsorption also occurs. No mammalian enzyme is known to mediate the catabolism of AGE moieties after the lysosomal hydrolysis of peptide bonds. We suggest the existence of a secretory process of resulting AGE-amino acids (free adducts) into urine, which could explain the presence of AGE-adducts such as pentosidine in the urine of diabetic patients. These pathways, which depend on glomerular filtration and tubular function, are severely compromised in chronic and end-stage renal failure (Thornalley, 2005a, 2006). Due to this fact, AGE adducts are one of the classical “middle toxins” associated with renal failure (Vlassara, 1994). With the arrival of sensitive LC-MS/MS techniques, a more comprehensive representation of the role of the kidney in AGE control emerged, including the fate of small peptides and free adducts (Agalou et al., 2005; Rabbani and Thornalley, 2009; Rabbani et al., 2007; Thornalley, 2005b; Thornalley and Rabbani, 2009). Key AGEs have been described and shown in Figure 1.

The Influence of AGE Buildup and Its Impact on Aging

There is significant evidence for the buildup of AGEs with aging in multiple species. Contributions from the Baynes, Thorpe, and Monnier laboratories over the past three decades have been key in this area (Monnier and Taniguchi, 2016). The characterization of several cross-links present in collagen and their association with arterial disease have underscored their importance in diabetic complications as well as in aging (Baynes, 2001; Baynes et al., 1989; Dyer et al., 1991; Thorpe and Baynes, 2003). Based on a population-based study on adults aged 65 and older, high plasma carboxymethyl-lysine (CML) levels were found to be positively correlated with an increased risk of mortality in older adults due to all-cause mortality or cardiovascular disease (CVD) (Semba et al., 2009). Interestingly, the association of CML with increased mortality risk (all-cause or CVD) was found to be independent of diabetes mellitus (Semba et al., 2009).

Thus, AGEs may not just be a biomarker but also a potential driver of aging.

As depicted in [Figure 1](#), AGEs are a heterogeneous group of compounds that include more than 20 different products. These products that have been described further potentially mediate a wide variety of pathological effects ([Monnier et al., 2014, 2015](#); [Piperi et al., 2012](#); [Sveen et al., 2015](#)). Evidence of their accumulation in crystallins, collagens, and basement membranes has accumulated over the years. Several studies have addressed the buildup of AGEs in long-lived proteins ([Hammes et al., 1999](#); [Sell et al., 1992](#); [Vashishth, 2009](#)). One human study quantified autofluorescence of eye lens as an indicator of AGE accumulation with age ([Cahn et al., 2014](#)). The buildup of different AGEs (e.g., pentosidine) in the skin and increased crosslinking of collagen due to AGEs have been observed in the skin biopsies of diabetic patients ([Monnier et al., 2005](#); [Sell et al., 1992](#)). Pentosidine, a pentose-mediated protein cross-linking, is present in multiple types of human tissues including plasma proteins and red blood cells ([Sell and Monnier, 1989](#)). Similar work has underscored the importance of AGEs in bone health with age ([Yamagishi, 2011](#)). In particular, the extracellular matrix is an important compartment for the buildup of AGEs due to the presence of long-lived proteins like collagen ([Singh et al., 2014](#)). Accumulation of AGEs has also been suggested to contribute to the accumulation of lipofuscin with age ([Nowotny et al., 2014](#)).

The above evidence, although suggestive, is merely correlative. Evidence for a direct and causal relationship of AGEs with lifespan comes from studies in *C. elegans*. Overexpression of the glyoxalase GLOD-4 in worms extends lifespan and also inhibits dicarbonyl-mediated modification of mitochondrial proteins by AGEs ([Morcos et al., 2008](#)). Loss of function of GLOD-4, on the other hand, shortens lifespan, which is exacerbated under high glucose conditions in *C. elegans* ([Chaudhuri et al., 2016](#)). Interestingly, a recent study has shown that low concentrations of MGO, formed via inactivation of the enzyme glycine-C-acetyltransferase (GCAT) involved in threonine catabolism, can promote lifespan through proteohormesis ([Ravichandran et al., 2018](#)). Reduction of age-related accumulation of AGEs by the FDA-approved (for the treatment of tuberculosis [TB]) drug Rifampicin also enhances worm lifespan through activation of DAF-16/FOXO ([Golegaonkar et al., 2015](#)). The additional evidence underlying the role of AGEs in determining lifespan comes from studies correlating the levels of AGEs in different species. Previous results from the Monnier group have shown that the accumulation of pentosidine in skin samples varies at a rate inversely related to maximum lifespan. This has been studied across eight mammalian species ([Sell et al., 1996](#)). Thus, there is significant evidence on the effect of AGEs in the aging process and for their causal influence on rates of organismal aging. We further discuss the evidence for the role of AGEs in age-associated diseases below.

AGEs and Their Link with Age-Related Diseases in Humans

Prolonged hyperglycemia in diabetes leads to a number of pathologies collectively termed diabetic complications. These include neuropathy, cardiomyopathy, nephropathy, and retinopathy ([Singh et al., 2014](#)). One of the most compelling explanations for the molecular basis of diabetic complications is the buildup of glucose catabolism-derived reactive byproducts,

the α -DCs ([Henning et al., 2014](#)). Notably, accumulation of MGO greater than 600 nM in the plasma distinguishes diabetics with pain and no pain in humans ([Bierhaus et al., 2012](#)). Variations in susceptibility to diabetic complications under similar glycemic levels could potentially be due to differences in detoxification of these α -DCs and associated AGEs. Notably, the active involvement of AGEs has also been implicated in age-related neurodegenerative diseases ([Castellani et al., 1996](#)). A key question in the field is whether AGEs are passive bystanders or if they actively contribute to cellular damage. A direct role for AGEs has been shown in mice by administering synthetic AGEs (derived from MGO treatment of BSA) that enhanced the accumulation of triglycerides and premature development of insulin resistance due to the reduction in anti-AGE receptor 1 (AGER1) and sirtuin 1 (SIRT1) in various tissues ([Cai et al., 2012](#)). Diet-derived AGEs have also been shown to exacerbate conditions of diabetic complications resulting in accumulation of pro-inflammatory factors such as tumor necrosis factor- α (TNF- α) and interleukin-6 (IL-6) in the serum of streptozotocin-induced diabetic mice ([Lv et al., 2016](#)). AGEs also lead to significant vascular complications and damage to organs such as the heart and kidney ([Lv et al., 2016](#)). These studies provide evidence behind the direct involvement of α -DCs such as MGO in mediating a variety of age-related disease complications.

Pathways Underlying AGE-Mediated Effects on Aging and Age-Related Diseases

The RAGE Pathway and Oxidative Stress: A Key Mechanism by which AGEs Participate in the Pathogenicity of Chronic Diseases

AGEs likely contribute to the age-related increase in inflammation or “inflammaging” ([Franceschi and Campisi, 2014](#)). They are ligands to several pro- and anti-inflammatory cellular receptors. A key pro-inflammatory receptor is the receptor for advanced glycation end-products (RAGE), a multi-ligand protein discovered and isolated from bovine lung ([Coughlan et al., 2007](#); [Miyata et al., 1996](#); [Rodríguez-Ayala et al., 2005](#); [Schmidt and Stern, 2000](#); [Schmidt et al., 1996](#); [Tanji et al., 2000](#); [Yamagishi, 2011](#)). RAGE belongs to the immunoglobulin superfamily of receptors and coordinates intracellular RAGE signaling ([Daffu et al., 2013](#)). As depicted in [Figure 4](#), besides AGE adducts, RAGE binds a wide array of ligands including the leukocyte integrin Mac-1, S100/calgranulins, high mobility group box 1 protein (HMGB1), modified LDL, DNA, RNA, and amyloid fibrils. These ligands bear similar structural features: multiple β sheets. RAGE identifies its ligands through them ([Ramasamy et al., 2011](#); [Yan et al., 2010a](#)). Upon ligand binding, RAGE starts a signaling cascade with activation of nuclear factor- κ B (NF- κ B), oxidative stress, and inflammation as shown in [Figure 4](#). RAGE signals via phosphatidylinositol-3 kinase (PI-3K), Ki-Ras and the MAPKs, Erk1, and Erk2 ([Ramasamy et al., 2011](#); [Yan et al., 2010a](#)). These pathways orchestrate the translocation of NF- κ B from the cytoplasm to the nucleus stimulating inflammation and tissue injury operated by the RAGE-dependent expression of pro-inflammatory mediators such as monocyte chemoattractant protein-1 (MCP-1) and vascular cell adhesion molecule-1 (VCAM-1). Through these pathways, RAGE activity is associated with diabetic microvascular complications including nephropathy, retinopathy, and neuropathy ([Ramasamy et al., 2011](#); [Yan](#)




Figure 4. The Receptor for Advanced Glycation End Products (RAGE) Is a Key Pathway for Inflammatory Complications in Aging and Chronic Disease

As shown in the top part of the figure, RAGE is a pattern recognition receptor that participates in primary immunity and has a variety of ligands. Important for our topic are the AGE, AGE-proteins, AGE-peptides, and adducts from primary AGE catabolism and dietary AGEs. RAGE activation leads to a signaling cascade that produces NF- κ B coordinated inflammatory responses that can lead to target tissue injury. Soluble forms of the receptor (esRAGE and sRAGE) are released to the circulation. Some authors suggest they serve to modulate the response, acting as decoy ligands. They are useful as biomarkers of the whole-body AGE-RAGE axis.

et al., 2010a). Besides these cascades leading to inflammation, in endothelial (glomerular) and mesangial cells, RAGE activation increases reactive oxygen species (ROS). As we illustrate in Figure 4, a protagonist role is taken by reduced nicotinamide adenine dinucleotide phosphate, NAD(P)H oxidase, which, in analogy to what happens in neutrophils, is a significant player in oxidative stress and dysfunction (D'Agati and Schmidt, 2010). The extracellular domain of RAGE is present in the bloodstream and may play a role in cardiovascular disease and chronic diseases (Figure 3). The C-terminal truncated form of RAGE mRNA lacks the encoding sequences for the transmembrane and intracytoplasmic domains (Forbes et al., 2005; Kalousová et al., 2007; Nakashima et al., 2010). The truncated version (endogenous secretory RAGE: esRAGE) is released and found in the circulation in humans. This esRAGE cancels the effects of AGEs on cells in culture (Bowman and Schmidt, 2013), and overexpression of esRAGE in mice reverses diabetic vascular dysfunction. Hence, esRAGE may play a decoy function; a feedback mechanism has been proposed by which esRAGE prevents RAGE signaling. Another form of soluble RAGE (sRAGE) (Figure 4) stems from proteolytic cleavage of the native RAGE expressed on the cell surface; both may act as decoys protecting from excessive ligand binding to RAGE and its consequent inflammatory cascades (Leonardis et al., 2012; Raposeiras-Roubín et al., 2010; Vazzana et al., 2009; Yan et al., 2010b). Further, the protective effect of esRAGE against dopaminergic neuronal death through inhibition of AGE-albumin buildup suggests the direct link between AGE-RAGE interaction and neurodegeneration (Bayarsaikhan et al., 2016).

Is AMPK a Key Target for Damage by MGO that Impairs Metabolism?

Another mechanism by which MGO stress may be implicated in metabolic disease and especially in the metabolic syndrome (MetS) is by its putative action against AMPK. AMPK induces a

cascade of events within cells in response to the fluxes and availability of metabolites. The role of AMPK in regulating cellular energy status (by sensing low energy using [AMP] as its signal) and activating catabolic pathways while inhibiting anabolic routes places this enzyme at a central control point in maintaining energy homeostasis. Once activated, AMPK-mediated downstream phosphorylation events switch cells from active ATP production to active ATP production. Thus, it increases glucose transport, glycolysis, and beta-oxidation, and inhibits lipogenesis and cholesterol biosynthesis. The mammalian AMPK is a trimeric enzyme composed of a catalytic α subunit and non-catalytic β and γ subunits. The N-terminal half of the α subunits contains a typical serine/threonine kinase catalytic domain. Direct AMP-binding studies have shown that AMP is bound to the γ subunits by a pair of so-called Bateman's domains. Three arginine residues are the binding site for AMP (the binding is electrostatic, and not the AMP-Mg⁺⁺ complex, but free AMP, is sensed), making this allosteric site vulnerable to carbonyl attack, especially by MGO.

A very small rise in AMP levels can induce a dramatic increase in the activity of AMPK, which suggests that blocking of the AMP allosteric sites, even minimally, can have amplified reduction in AMPK activation. We proposed that an increased flux of MGO could achieve this effect. This increased flux may be produced by fructose surges (excess sugar in the diet, especially liquid), hyperglycemia, as well as an overflow of the glycolytic pathway caused by inactivation of glyceraldehyde-3-P dehydrogenase (GAPDH), in turn induced by its direct oxidation by ROS or indirectly by their activation of polyadenybosyl polymerase (PARP) as proposed by Michael Brownlee (Brownlee, 2005). Inactivation of AMPK would favor lipogenesis, insulin resistance, and hyperglycemia, all hallmarks of MetS and diabetes (Gugliucci, 2009, 2016, 2017).

The Impact of AGEs on Diabetes-Associated Complications Peripheral Neuropathy

Some of the strongest evidence of the role of AGEs in diabetic complications comes from mice studies in peripheral




Figure 5. Glycation and Diabetic Neuropathy: An Example of Pathways and Targets where AGEs, MGO, and Carbonyl Stress Play an Important Role

Evidence shows that a triple hit may be operating to produce the final damage: vasa vasorum, the Schwann cell, and the neuron axon; all three are targets for the damage. Hyperglycemia produces AGEs via the mechanisms shown here and in detail in Figure 1. The interplay with oxidative stress (depletion of glutathione) activates MAPK and its inflammatory cascades, which produces vascular damage via PKC β . Oxidative stress on DNA induces the repair enzyme PARP, which has the drawback of inactivating GAPDH, therefore blocking glycolysis at the triose level with the upstream consequence of further MGO accumulation, compounding the problem (Brownlee's hypothesis, see text). Final damage occurs to the neuronal axon, neuronal mitochondria, and the glial Schwann cells.

neuropathy. As an example, we depict a summary of those pathways in Figure 5. To understand the important role of glycation in diabetic neuropathy one should consider that the neural deficit is the consequence of a metabolic shift at three levels: the endothelium of the vasa nervorum, the sensory neuron (dorsal root ganglia) axon, and the Schwann cell (glia) (Münch et al., 2012). Figure 5 illustrates some characteristics of this triple hit, which bear common pathways in all cells as well as specific differences in others. Hyperglycemia leads to polyol and fructose accumulation (fructose is 7 times more reactive than glucose), NADPH and GSH depletion, and oxidative/nitrosative stress. This damages DNA, which induces the repair enzyme poly (ADP-ribose) polymerase (PARP) activity. PARP inactivates GAPDH, blocking the second phase of glycolysis, leading to MGO accumulation and more glycation and damage. Protein kinase C beta (PKC β) is activated in the vasa nervorum as a result of these metabolic shifts, and inflammatory damage to the endothelium ensues, leading to increased permeability and cell death. Conversely, protein kinase C alpha (PKC α) is inactivated in neuronal axons, which induces dysfunction. Glycation of the extracellular matrix molecules impairs nerve regeneration, compounding the problem. Dorsal root neuron RAGE is increased, and so are the NF- κ B cascade responses. When protracted, these changes are damaging to neurons, which do not reproduce and therefore accumulate the damage. Lastly, MAPK pathways are activated by the same metabolic shifts leading to COX 2 activation with potent pro-inflammatory components (Münch et al., 2012). In support of these general pathways, variation in Glo1 abundance among mice strains has been shown to lead to a differential

response of sensory neurons to dicarbonyl stress (Jack et al., 2011). In another study in mice, it was found that post-translational modifications in the voltage-gated sodium channel Na(v) 1.8 induced by plasma methylglyoxal results in hyperalgesia (Bierhaus et al., 2012). This study was crucial in delineating a novel therapeutic target for dicarbonyl-mediated diabetic neuropathy. In addition, and consistent with the latter, the dicarbonyl-sensitive neuronal receptor TRPA1 (Transient Receptor Potential cation channel A1), was shown to mediate pain in Trpa1 null mice and the agonist, methylglyoxal, to activate the receptor in mammalian cell culture (Andersson et al., 2013). More recently, hyperpolarization-activated cyclic nucleotide-gated 2 (HCN2) ion channels in mice have also been identified to be a potential therapeutic target for neuropathy, a condition that develops progressively with age in diabetic patients (Tsantoulas et al., 2017). In conclusion, AGEs participate in the triple hit at the basis of diabetic neuropathy by acting on vasa nervorum, neurons, and glia.

Diabetic Nephropathy

In addition to diabetic neuropathy, the role of α -DC-derived AGEs has also been implicated in diabetic nephropathy (Rabbani and Thornalley, 2018a). Knockdown of the α -DC detoxification gene glyoxalase I (Glo1) in non-diabetic mice recapitulates diabetic nephropathy symptoms without hyperglycemia (Giacco et al., 2014). Some features of AGE-mediated diabetic nephropathy, namely myofibroblast-based fibrosis, has also been modeled in a rat proximal tubule cell line by inducing transdifferentiation of epithelial cells into myofibroblasts using labeled AGE (125 I-AGE-BSA). AGE-RAGE signaling elicits this response by stimulating the production of TGF- β and other cytokines, which in turn trigger transdifferentiation (Oldfield et al., 2001). Endothelial damage and early renal dysfunction also seem to result from AGE accumulation. Thus, the appearance of this phenotype was inhibited in streptozotocin-treated Glo1 overexpressing rats (Brouwers et al., 2014). Similarly, overexpression of Glo1 completely prevented hyperglycemia-induced renal pathology, possibly by lowering induced oxidative stress mediated by α -DC induced glomerular protein modifications (Giacco et al., 2014).

Diabetic Macroangiopathy

The detoxification of α -DCs, a precursor of AGE, also underlies the prevention of diabetes-mediated micro and macro vascular damage that may contribute to atherosclerosis and stroke (Brownlee, 2001, 2005). In support of the role of AGEs in vascular derangement, intravenous (IV) administration of AGEs in healthy rats significantly triggered the expression of vascular endothelial growth factor (VEGF) and inhibited pigment epithelium-derived factor (PEDF) levels that lead to diabetic retinopathy due to enhanced vascular permeability (Yamagishi et al., 2006). AGEs also induce diabetic macroangiopathy primarily by interacting with the endothelial cells lining the walls of the blood vessels. The latter activity results in a pro-inflammatory cascade followed by vascular dysfunction (Basta et al., 2004). Along similar lines, but involving a different endpoint, it was earlier reported that both *in vitro* and *in vivo* administration of aminoguanidine (a nucleophilic hydrazine compound that prevents AGE cross-linking) inhibits AGE formation and subsequent age-related increase in collagen cross-linking in the wall of the arteries (Brownlee et al., 1986).

Dietary AGEs and Obesity

In addition to AGE accumulation via the endogenous route, exogenous sources such as diet also contribute significantly to a number of AGE-related pathologies. Thus, in mice, dietary AGEs supplemented with high fat (high AGE-high fat or HAGE-HF) resulted in hepatosteatosis and steatohepatitis, both characteristics of non-alcoholic fatty liver disease or NAFLD (Sayej et al., 2016). In addition to gaining weight, treated animals also showed secretion of various inflammatory cytokines from the adipose tissue (Sayej et al., 2016). The latter finding is consistent with the effects of standard Western diet, a major source of AGEs as a causative factor behind chronic inflammation and oxidative stress leading to insulin resistance (IR) (Gugliucci, 2017; Uribarri et al., 2015; Vlassara and Uribarri, 2014).

Modeling the Influence of AGEs in Neurodegenerative Diseases

Parkinson's Disease

In addition to diabetic complications, AGEs are also known to contribute to age-related neurodegeneration (reviewed in Münch et al., 2012). For example, a diet with high glycemic index, when fed to mice, has been shown to cause a significant increase in the formation of AGEs in the brain, primarily in the substantia nigra (Uchiki et al., 2012). In addition, glycation-mediated AGE formation has been reported at the periphery of Lewy bodies in PD patients (Castellani et al., 1996). Lewy bodies are aggregations of intracytoplasmic inclusions in the subcortical neurons in PD patients (Trojanowski et al., 1998). In cases of incidental Lewy body disease, AGEs appear in newly formed Lewy bodies, further suggesting that AGEs may play a critical role in triggering Lewy body formation in pre-PD individuals (Münch et al., 2000).

Further evidence of the role of AGEs in neurodegenerative diseases comes from the findings that *DJ1*, glutathione-independent glyoxalase, involved in the detoxification of AGEs, is associated with familial, early-onset, and sporadic forms of PD (Lee et al., 2012). This protective role of *DJ-1* against dicarbonyls was modeled using mouse embryonic fibroblast and human SH-SY5Y cell models for dopaminergic neurons (Lee et al., 2012). In addition, studies using cell culture and *C. elegans* suggest that the glyoxalase function of *DJ-1* is critical for neuroprotection against toxic oxaldehydes (Lee et al., 2012). Further, using human and mice primary cells, *DJ-1* has also been identified as a stabilizer of Nrf2 under conditions of toxicity-related stress (Clements et al., 2006; Im et al., 2012; Xue et al., 2012). Thus, the loss of *DJ-1* function may lead to increased levels of methylglyoxal and AGEs, making it an attractive therapeutic target for diseases associated with oxidative stress (Ariga et al., 2013). At the mechanistic level, the relationship between AGEs and PD could also be due to the ability of AGEs to cross-link alpha-synuclein, as has been shown using *in vitro* studies (Shaikh and Nicholson, 2008). A recent study has shown that glycation of α -synuclein, a protein whose aggregation is the hallmark of PD, enhanced the aggregation and reduced clearance of toxic oligomers. *In vitro* and *in vivo* studies using flies and mice showed that enhanced glycation is toxic, while glycation inhibitors reduce aggregation and enhance clearance of α -synuclein and rescue behavioral phenotypes (Vicente Miranda et al., 2017). Furthermore, these studies also explain the significantly increased risk of PD among diabetics.

Alzheimer's Disease

In addition to PD, AGEs have also been associated with Alzheimer's disease (AD). Previous studies suggest that the glycation of such AD-associated proteins such as A β and tau play a critical role in the pathogenesis of this disorder. For example, plaques extracted from AD brains show a 3-fold increase in AGE content compared to age-matched healthy individuals (Vitek et al., 1994). Also, AGEs have been suggested to stabilize and promote the formation of aggregated forms of A β and tau (Chen et al., 2006; Ledesma et al., 1994; Woltjer et al., 2003). More specifically like PD, glycation is considered to be responsible for the increase in the cross-linking of A β and tau proteins and the subsequent formation of stable oligomeric forms. Additional direct evidence favoring an AGE-AD connection comes from *in vitro* studies using neuroblastoma cell lines and *in vivo* experiments involving mice. These experiments show that glycation (AGE formation) also upregulates the expression of the amyloid precursor protein (APP), an enhancement that increases A β peptide levels (Ko et al., 2010) that can in turn trigger phosphorylation of tau proteins as characterized in rat septal cholinergic neurons (Zheng et al., 2002). In addition to phosphorylating tau proteins, an important hallmark of the disease, AGEs also colocalize with other markers of neurodegeneration, such as nNOS (a nitrooxidative stress marker) and caspase-3 (an apoptotic cell-death marker) (Lüth et al., 2005). The connection between glycated protein levels in the cerebrospinal fluid (CSF) of AD patients (Ahmed et al., 2005; Li et al., 2013) further reinforces the importance of glycated A β as a potential mechanism for disease progression. It has been shown consistently that there is a significant buildup of AGEs in serum and CSF of patients with AD compared to controls (Ahmed et al., 2005). Thus, it seems reasonable to postulate that the age-dependent decrease in glyoxalase levels and a concomitant increase in AGE buildup contributes, at least in part, to the increased incidence of Alzheimer's and other neurodegenerative diseases (Kuhla et al., 2007). These studies may also help explain mechanisms underlying the epidemiological evidence that suggest a link between type 2 diabetes and AD (Li et al., 2015).

Potential Factors Underlying AGE-Mediated Effects on Neurodegeneration

Inflammation. Inflammation downstream of AGE production has been implicated as the key mechanism contributing to diseases. For instance, AGE-albumin in the extracellular space of human microglial cells triggers the generation of multi-ligand receptors for AGE or RAGE on cell membranes (Bayarsaikhan et al., 2016). The RAGE interaction with the secreted AGE-albumin complexes has been shown to mediate an apoptotic cascade leading to the death of human dopaminergic neurons. Elevated AGE-albumin accumulation from activated microglia has been suggested as a potential biomarker for neurodegenerative diseases (Bayarsaikhan et al., 2016). Activation of macrophages leads to an exacerbated release of AGE-albumin complexes, a major AGE derivative that drives shared pathways resulting in the progression of neurodegeneration (Byun et al., 2017). Upregulation of RAGE-mediated signaling has also been shown in the 6-hydroxydopamine (6-OHDA) induced rat model for neurotoxicity (Serratos et al., 2016).

Cellular Stress and Decreased Proteostasis. Other than AGE-RAGE interaction enhancing inflammation, one of the key

mechanisms that lead to AGE-mediated neurodegeneration is the generation of cellular stress and decline in proteostasis with age. This stems from the damage caused by AGEs to proteins and the subsequent crosslinking and accumulation in aggregates. Accumulation of AGEs potentially through such cross-linking events results in sustained cellular stress, eventually leading to neuronal cell death (Guerrero et al., 2013). Such increased cellular stress can also happen due to activation of RAGE-like receptors (Hipkiss et al., 2013; Peppas and Vlasara, 2005).

Glycation of Neurotransmitters. Moreover MGO, besides proteins, may selectively modify dopamine. The reaction leads to toxic metabolites like 1-acetyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (ADTIQ) (Deng et al., 2012). This active metabolite is present in human brain tissue, including the substantia nigra. ADTIQ levels are increased in PD patients (Deng et al., 2012), and the structure of ADTIQ resembles that of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) elucidated using hyperglycemic cell and rat models (Song et al., 2014). Interestingly, in a separate study, ADTIQ has been shown as an endogenous neurotoxin in SH-SY5Y neuroblastoma cells, and the levels of both MGO and ADTIQ are increased in the striatum of a streptozotocin-induced diabetic rat model (Xie et al., 2015).

Despite our mechanistic understanding of the AGE-mediated effects in the pathology of age-related diseases, designing viable therapeutic strategies can be a challenge without modeling the disease in experimental organisms and without a better understanding of the pathways targeted by AGES and those involved in AGE formation and detoxification.

Using Invertebrate Models to Study the Impact of AGEs

To better understand the role of AGEs in modulating age-related disease, there is an urgent need for suitable models to study the biological mechanisms of AGE formation, detoxification, and link to the disease pathology in a short time frame. This is a major bottleneck in our current understanding of the biochemistry of AGE formation and its consequences, and hence rapid drug development to combat the associated pathologies. To that end, there has been a considerable effort to model AGE accumulation in a variety of model organisms ranging from invertebrates to vertebrates in order to gain a mechanistic insight (Table 1). These studies also highlight the importance of model organisms in designing and delineating putative therapeutic targets that could have otherwise been extremely challenging to determine. A good model to study long-term AGE-related complications should have the following characteristics: (1) recapitulate at least some of the pathologies associated with α -DC and AGE buildup, (2) recapitulate the buildup of AGEs in an age-dependent manner in a short time frame, and (3) be amenable to high-throughput genetic and drug screens.

Vertebrate model organisms such as rodents are a natural first choice to model AGE-mediated pathologies, due to the relatively close link to human disease biology and a track record as a model for studying disease pathology in diabetes (King, 2012). However, a rodent's relatively long lifespan and associated cost of maintenance pose limitations to conduct rapid genetic or drug screens or to serve as a model that recapitulates the effects of aging while studying AGE-mediated pathologies. Using *C. elegans*, it has been shown that *glod-4*, an ortholog of

mammalian Glo1 glyoxalase, plays a critical role in regulating worm lifespan (Morcos et al., 2008). This study enabled the understanding of the long-term effects of dicarbonyl-mediated damage of mitochondrial proteins via generation of enhanced mitochondrial ROS that was rescued by the glyoxalase overexpressing animals (Morcos et al., 2008). Also, *C. elegans* displayed endogenous accumulation of dicarbonyls and AGEs as the glyoxalase I activity declined with age (Morcos et al., 2008). In our recent study, we have utilized the *C. elegans* mutant for *glod-4* as a model to study diabetic complications. The *C. elegans glod-4* mutant accumulates toxic α -DCs and exhibits several diabetes-related pathologies akin to the mouse model. These include accumulation of α -DCs, hyperesthesia (or hyper sensitivity to touch), neuronal damage, and early mortality, in a glucose-dependent fashion (Chaudhuri et al., 2016). The short-lived *glod-4* mutant has also been shown to accumulate a broad variety of AGE-modified proteins (Golegaonkar et al., 2015). Furthermore, the powerful genetic tools available to study *C. elegans* led to the identification of a conserved and critical role for TRPA-1 in sensing MGO and also in SKN-1/Nrf2 activation to detoxify α -DCs. In addition, we utilized the worm to undertake a phenotypic drug screen for neuropathy by screening for compounds that reduce the increased hypersensitivity to touch in *glod-4* mutants. This screen has identified several novel pharmacological leads, including Podocarpic and lipoic acid as activators of *TRPA1* that ameliorate the deleterious consequences of MGO accumulation in *C. elegans* (Chaudhuri et al., 2016). The relevance of a worm model to study diabetic complications is underscored by the facts that Nrf2 has been previously shown to play an important role in ameliorating diabetic pathologies in mice (Jiang et al., 2010; Li et al., 2012; Zheng et al., 2011) and that lipoic acid is used clinically for diabetic nephropathy (McIllduff and Rutkove, 2011; Ziegler et al., 1999).

Other studies have also utilized *C. elegans* or *D. melanogaster* to study MGO and AGE stress. *C. elegans* has been modeled to study glucose toxicity due to AGE-mediated modification of mitochondrial proteins (Schlotterer et al., 2009). A reduction of AGE-mediated glycation by the Rifampicin has been shown to extend *C. elegans* lifespan through the activation of DAF-16/FOXO signaling (Golegaonkar et al., 2015). A study in fruit flies demonstrated that the mutant for the glycolytic enzyme, triose phosphate isomerase (TPI) leads to increased neurodegeneration (Gnerer et al., 2006). TPI is a key isomerase that converts dihydroxyacetone phosphate (DHAP) to glyceraldehyde-3-phosphate (GAP), and in its absence, DHAP non-enzymatically generates increased concentrations of MGO and thus AGEs (Gnerer et al., 2006). In another study using flies, a mutant for the fatty acid synthase (*FASN*) gene was used to understand the interplay between dietary sugar, MGO, and lipogenesis (Garrido et al., 2015). Their study demonstrates the requirement for fatty acid synthesis to prevent the potentially detrimental intracellular buildup of MGO-derived AGEs (Garrido et al., 2015). In addition to invertebrate animal models such as worm and flies, another model system frequently utilized to characterize glycation mediated protein damage is *S. cerevisiae* (yeast). In a recent study, mutants that enhance MGO production were used to understand glycation-mediated protein misfolding associated with huntingtin protein in yeast, flies, and human cells (Vicente Miranda et al., 2016). The key finding in the study was

Table 1. Summary of Model Organisms, Phenotypes, and Genes/Proteins/Pathways Related to α -DC or AGE-Mediated Pathologies that Exacerbate with Age

Model Organism	Phenotypes	Genes/Proteins/Pathways	References
Mice/Rats	neuropathy, nephropathy, neurodegeneration, cardiomyopathy, retinopathy, vasculopathy	<i>TGF-β</i>	Oldfield et al., 2001
		<i>VCAM1</i>	Schmidt et al., 1995
		<i>RAGE</i>	Bayarsaikhan et al., 2016; Ma et al., 2009
		<i>VEGF</i>	Yamagishi et al., 2006
		<i>Na_v 1.8</i>	Bierhaus et al., 2012
		<i>GLO1</i>	Jack et al., 2011
		<i>TRPA1</i>	Andersson et al., 2013
		<i>HCN2</i>	Tsantoulas et al., 2017
		<i>DJ-1</i>	Lee et al., 2012
		<i>NF-κB</i>	Zhou et al., 2016
Fly	neurodegeneration, paralysis, fat accumulation, lifespan	<i>Glo1</i>	Garrido et al., 2015; Gnerer et al., 2006
		<i>FASN</i>	Garrido et al., 2015
		<i>Tpi</i>	Gnerer et al., 2006
		<i>wstd</i>	Gnerer et al., 2006
Worm	neurodegeneration, hyperesthesia, lifespan	<i>TRPA-1</i>	Chaudhuri et al., 2016
		<i>Nrf</i>	Chaudhuri et al., 2016
		<i>p38 MAPK</i>	Chaudhuri et al., 2016
		<i>DJ-1</i> related (<i>djr-1.1</i> & <i>djr-1.2</i>)	Chaudhuri et al., 2016; Chen et al., 2015; Golegaonkar et al., 2015; Lee et al., 2012; Lee et al., 2013, 2012
		<i>GLOD-4</i>	Chaudhuri et al., 2016; Chen et al., 2015; Golegaonkar et al., 2015; Mender et al., 2015; Morcos et al., 2008
		<i>DAF-18</i>	Golegaonkar et al., 2015
		<i>JNK-1</i>	Golegaonkar et al., 2015
<i>DAF-16</i>	Golegaonkar et al., 2015; Mender et al., 2015		
Yeast	proteotoxicity, proteostasis	<i>Glo1</i>	Vicente Miranda et al., 2016; Gomes et al., 2008; Zemva et al., 2017
		<i>Tpi</i>	Vicente Miranda et al., 2016
		<i>Hsp26p</i>	Gomes et al., 2008
		<i>Hsp104</i>	Zemva et al., 2017
		<i>ALKR</i>	Zemva et al., 2017
		<i>Sln1</i>	Zemva et al., 2017
		<i>Hog1</i>	Zemva et al., 2017

that glycation enhanced the aggregation and inhibited clearance of HTT, the gene that encodes for huntingtin, suggesting a direct role of protein glycation in neurodegeneration (Vicente Miranda et al., 2016). In a recent study utilizing flies and mice, it was also shown that accumulation of toxic oligomers due to age-related glycation of α -synuclein resulted in disruption of synaptic transmission in the neurons (Vicente Miranda et al., 2017).

The vertebrate, invertebrate, and cell culture models suggest the direct involvement of AGEs in mediating a broad spectrum of disease pathologies and also the feasibility to gain a mechanistic understanding of these processes. In particular, the use of short-lived animal models has allowed one to monitor the progression of pathology and its link with AGEs. Overall, the evidence linking AGEs with diabetic complications and neurodegenerative diseases is emerging, but the mechanisms by which they influence disease progression and genetic networks involved in modulating AGEs remain poorly understood. Greater

utilization of expedient genetic models should help reveal the mechanisms in place to reduce the accumulation of AGEs.

Glyoxalases as a Target for Therapy

Thus, given the evidence implicating AGEs in diabetic complications, detoxification of AGEs represents an orthogonal approach to the treatment of diabetes in addition to lowering glucose. Given the success of aminoguanidine (also known as Pimagidine) in animal models, a human clinical trial was conducted to prevent diabetic kidney disease (Freedman et al., 1999). Unfortunately, the trial was discontinued due to side effects (Thornalley, 2003), which has led to reduced enthusiasm in the field that lowering AGEs would be a successful strategy in treating age-related diseases. However, there is need to devise novel approaches to lower AGEs by harnessing the endogenous defenses in place, which are likely to prevent AGE formation and potentially pose fewer side effects. In a recent promising clinical

trial, a combination therapy of trans-Resveratrol (tRes) and Hesperetin (HESP) helped improve glycemic control and vascular inflammation in healthy overweight and obese individuals via induction of Glo1 (Rabbani and Thornalley, 2018b). This suggests that inhibition of MGO accumulation via induction of glyoxalases could be a potential therapeutic strategy for glycation-mediated diseases.

Glyoxalase expression and activity are shown to be regulated by the nuclear factor erythroid 2-related factor 2 (Nrf2) (Xue et al., 2012), a basic leucine zipper (bZIP) protein that also regulates the expression of other antioxidant proteins (Rabbani and Thornalley, 2015b). This is due to the presence of stress-response-related regulatory elements such as AREs (antioxidant-response elements) on the 5' flanking region of the Glo1 gene (Xue et al., 2012). Urine samples from 10-week-old Nrf2^{-/-} mice compared with age-matched controls showed significant accumulation of AGEs such as MGdG and MG-H1 as well as macromolecular damage (Xue et al., 2012). Similar results were described by our group using *C. elegans* (Chaudhuri et al., 2016). Furthermore, we found that the Nrf2-mediated regulation of both the glutathione-dependent and independent glyoxalases (*GLO1* and *DJ1*) is mediated by the activation of the cation channel *TRPA1*, an upstream sensor for α -DCs (Chaudhuri et al., 2016). Sensing of dicarbonyls by *TRPA1* is relayed to the transcription factor SKN-1/Nrf via MAP kinase-mediated signaling and ultimately enhances the expression of Glo1 and Dj1 to initiate the detoxification program (Chaudhuri et al., 2016). Chronic activation *in vitro* in the vascular endothelial cells of diabetic rats of the nuclear factor- κ B (NF- κ B), downstream of AGE activation of RAGE, has also been shown to regulate glyoxalases (Bierhaus et al., 2001). Thus, given the evidence for Nrf2 in detoxifying AGEs across species, it represents an excellent target to mitigate AGEs and associated diseases.

Conclusions

We have a limited understanding of the causal effects of both dietary and endogenous AGEs on aging and age-related diseases. More importantly, many aspects of AGE accumulation, including how they are formed, sensed, and detoxified, remain poorly understood. Regulatory mechanisms that underlie these pathways are potential targets for human diseases. There is a significant need to develop therapeutics that lower AGEs and can serve as an orthogonal approach to treat various age-related human metabolic diseases, like metabolic syndrome, diabetic complications, as well as neurodegenerative diseases. Vertebrate and invertebrate model systems with a genetically impaired glyoxalase system have been instrumental in assessing the extent of α -DC and AGE-mediated disease pathologies and mechanisms. Invertebrate model organisms have the advantage to recapitulate AGE-mediated pathologies over a short time frame, which otherwise takes years to build up in humans. The worm, fly, and yeast models with their relatively short lifespans and easy-to-use genetic tools could help answer some of the complex mechanistic questions associated with diseases such as obesity, neurodegeneration, and diabetic complications in a much more rapid manner. The combination of AGE-mediated stress with existing human disease models is likely to better mimic the age-related disease pathology in humans. They could also be used as a tool for a high-throughput drug screening plat-

form to identify novel pharmaceutical leads for these diseases. A key limitation to using certain invertebrate models could be trying to model AGE-related disease complications associated with organs, such as the bone, the heart, and the vascular system. The initial discoveries of disease mechanisms or mode of action for drug molecules from high-throughput screens made possible in invertebrates could be further validated in vertebrate model systems in pre-clinical trials. Importantly, despite certain drawbacks from a physiological point of view, utilizing the strength of invertebrate model systems in gaining mechanistic insights and performing high-throughput small molecule and genetic screens could potentially fuel major discoveries. The use of invertebrate models allows the examination of these complex diseases through the lens of aging, which is normally harder to recapitulate in traditional pre-clinical models.

ACKNOWLEDGMENTS

This work was funded by grants from the American Federation for Aging Research (P.K.), Larry L. Hillblom Foundation (P.K.), the impact circle award (Buck), the NIH grants R21 AG053066 and RO1 AG045835 (P.K.), and Touro University California. J.C. was supported by NIH/NIA T32 award (T32 AG000266), N.B. was supported by the Hillblom Foundation Postdoctoral Fellowship, A.G. is supported by NIH RO1 5RO1HL113887. We also thank the members of the Kapahi lab and Gugliucci labs for helpful discussions.

REFERENCES

- Agalou, S., Ahmed, N., Babaei-Jadidi, R., Dawnay, A., and Thornalley, P.J. (2005). Profound mishandling of protein glycation degradation products in uremia and dialysis. *J. Am. Soc. Nephrol.* *16*, 1471–1485.
- Ahmed, N., Ahmed, U., Thornalley, P.J., Hager, K., Fleischer, G., and Münch, G. (2005). Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. *J. Neurochem.* *92*, 255–263.
- Andersson, D.A., Gentry, C., Light, E., Vastani, N., Vallortigara, J., Bierhaus, A., Fleming, T., and Bevan, S. (2013). Methylglyoxal evokes pain by stimulating TRPA1. *PLoS One* *8*, e77986.
- Ariga, H., Takahashi-Niki, K., Kato, I., Maita, H., Niki, T., and Iguchi-Ariga, S.M.M. (2013). Neuroprotective function of DJ-1 in Parkinson's disease. *Oxid. Med. Cell. Longev.* *2013*, 683920.
- Baba, S.P., Barski, O.A., Ahmed, Y., O'Toole, T.E., Conklin, D.J., Bhatnagar, A., and Srivastava, S. (2009). Reductive metabolism of AGE precursors: a metabolic route for preventing AGE accumulation in cardiovascular tissue. *Diabetes* *58*, 2486–2497.
- Basta, G., Schmidt, A.M., and De Caterina, R. (2004). Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. *Cardiovasc. Res.* *63*, 582–592.
- Bayarsaikhan, E., Bayarsaikhan, D., Lee, J., Son, M., Oh, S., Moon, J., Park, H.J., Roshini, A., Kim, S.U., Song, B.J., et al. (2016). Microglial AGE-albumin is critical for neuronal death in Parkinson's disease: a possible implication for therapeutics. *Int. J. Nanomedicine* *10*, 281–292.
- Baynes, J.W. (2001). The role of AGEs in aging: causation or correlation. *Exp. Gerontol.* *36*, 1527–1537.
- Baynes, J.W., Watkins, N.G., Fisher, C.I., Hull, C.J., Patrick, J.S., Ahmed, M.U., Dunn, J.A., and Thorpe, S.R. (1989). The Amadori product on protein: structure and reactions. *Prog. Clin. Biol. Res.* *304*, 43–67.
- Bierhaus, A., Schiekofer, S., Schwaninger, M., Andrassy, M., Humpert, P.M., Chen, J., Hong, M., Luther, T., Henle, T., Klötting, I., et al. (2001). Diabetes-associated sustained activation of the transcription factor nuclear factor- κ B. *Diabetes* *50*, 2792–2808.
- Bierhaus, A., Fleming, T., Stoyanov, S., Leffler, A., Babes, A., Neacsu, C., Sauer, S.K., Eberhardt, M., Schnölzer, M., Lasitschka, F., et al. (2012).

- Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. *Nat. Med.* 18, 926–933.
- Bjorksten, J. (1968). The crosslinkage theory of aging. *J. Am. Geriatr. Soc.* 16, 408–427.
- Bowman, M.A.H., and Schmidt, A.M. (2013). The next generation of RAGE modulators: implications for soluble RAGE therapies in vascular inflammation. *J. Mol. Med. (Berl.)* 91, 1329–1331.
- Brouwers, O., Niessen, P.M.G., Miyata, T., Østergaard, J.A., Flyvbjerg, A., Peutz-Kootstra, C.J., Sieber, J., Mundel, P.H., Brownlee, M., Janssen, B.J.A., et al. (2014). Glyoxalase-1 overexpression reduces endothelial dysfunction and attenuates early renal impairment in a rat model of diabetes. *Diabetologia* 57, 224–235.
- Brownlee, M. (2001). Biochemistry and molecular cell biology of diabetic complications. *Nature* 414, 813–820.
- Brownlee, M. (2005). The pathobiology of diabetic complications: a unifying mechanism. *Diabetes* 54, 1615–1625.
- Brownlee, M., Vlassara, H., Kooney, A., Ulrich, P., and Cerami, A. (1986). Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. *Science* 232, 1629–1632.
- Bucala, R., Makita, Z., Vega, G., Grundy, S., Koschinsky, T., Cerami, A., and Vlassara, H. (1994). Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. *Proc. Natl. Acad. Sci. USA* 91, 9441–9445.
- Byun, K., Yoo, Y., Son, M., Lee, J., Jeong, G.B., Park, Y.M., Salekdeh, G.H., and Lee, B. (2017). Advanced glycation end-products produced systemically and by macrophages: A common contributor to inflammation and degenerative diseases. *Pharmacol. Ther.* 177, 44–55.
- Cahn, F., Burd, J., Ignatz, K., and Mishra, S. (2014). Measurement of lens autofluorescence can distinguish subjects with diabetes from those without. *J. Diabetes Sci. Technol.* 8, 43–49.
- Cai, W., Ramdas, M., Zhu, L., Chen, X., Striker, G.E., and Vlassara, H. (2012). Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. *Proc. Natl. Acad. Sci. USA* 109, 15888–15893.
- Castellani, R., Smith, M.A., Richey, P.L., and Perry, G. (1996). Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. *Brain Res.* 737, 195–200.
- Chaudhuri, J., Bose, N., Gong, J., Hall, D., Rifkind, A., Bhaumik, D., Peiris, T.H., Chamoli, M., Le, C.H., Liu, J., et al. (2016). A *Caenorhabditis elegans* Model Elucidates a Conserved Role for TRPA1-Nrf Signaling in Reactive α -Dicarbonyl Detoxification. *Curr. Biol.* 26, 3014–3025.
- Chen, K., Maley, J., and Yu, P.H. (2006). Potential implications of endogenous aldehydes in beta-amyloid misfolding, oligomerization and fibrillogenesis. *J. Neurochem.* 99, 1413–1424.
- Chen, P., DeWitt, M.R., Bornhorst, J., Soares, F.A., Mukhopadhyay, S., Bowman, A.B., and Aschner, M. (2015). Age- and manganese-dependent modulation of dopaminergic phenotypes in a *C. elegans* DJ-1 genetic model of Parkinson's disease. *Metallomics* 7, 289–298.
- Clements, C.M., McNally, R.S., Conti, B.J., Mak, T.W., and Ting, J.P.-Y. (2006). DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. *Proc. Natl. Acad. Sci. USA* 103, 15091–15096.
- Collard, F., Wiame, E., Bergans, N., Fortpied, J., Vertommen, D., Vanstapel, F., Delpierre, G., and Van Schaftingen, E. (2004). Fructosamine 3-kinase-related protein and deglycation in human erythrocytes. *Biochem. J.* 382, 137–143.
- Coughlan, M.T., Cooper, M.E., and Forbes, J.M. (2007). Renal microvascular injury in diabetes: RAGE and redox signaling. *Antioxid. Redox Signal.* 9, 331–342.
- D'Agati, V., and Schmidt, A.M. (2010). RAGE and the pathogenesis of chronic kidney disease. *Nat. Rev. Nephrol.* 6, 352–360.
- Daffu, G., del Pozo, C.H., O'Shea, K.M., Ananthakrishnan, R., Ramasamy, R., and Schmidt, A.M. (2013). Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond. *Int. J. Mol. Sci.* 14, 19891–19910.
- De Marco, E.V., Annesi, G., Tarantino, P., Nicoletti, G., Civitelli, D., Messina, D., Annesi, F., Arabia, G., Salsone, M., Condino, F., et al. (2010). DJ-1 is a Parkinson's disease susceptibility gene in southern Italy. *Clin. Genet.* 77, 183–188.
- Delgado-Andrade, C., and Fogliano, V. (2018). Dietary Advanced Glycosylation End-Products (dAGEs) and Melanoidins Formed through the Maillard Reaction: Physiological Consequences of their Intake. *Annu. Rev. Food Sci. Technol.* 9, 271–291.
- Delpierre, G., Vertommen, D., Communi, D., Rider, M.H., and Van Schaftingen, E. (2004). Identification of fructosamine residues deglycated by fructosamine-3-kinase in human hemoglobin. *J. Biol. Chem.* 279, 27613–27620.
- Deng, Y., Zhang, Y., Li, Y., Xiao, S., Song, D., Qing, H., Li, Q., and Rajput, A.H. (2012). Occurrence and distribution of salsolinol-like compound, 1-acetyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (ADTIQ) in parkinsonian brains. *J. Neural Transm. (Vienna)* 119, 435–441.
- Dunmore, S.J., Al-Derawi, A.S., Nayak, A.U., Narshi, A., Nevill, A.M., Hellwig, A., Majebi, A., Kirkham, P., Brown, J.E., and Singh, B.M. (2018). Evidence that differences in fructosamine-3-kinase activity may be associated with the glycation gap in human diabetes. *Diabetes* 67, 131–136.
- Dyer, D.G., Blackledge, J.A., Katz, B.M., Hull, C.J., Adkisson, H.D., Thorpe, S.R., Lyons, T.J., and Baynes, J.W. (1991). The Maillard reaction in vivo. *Z. Ernährungswiss.* 30, 29–45.
- Forbes, J.M., Thorpe, S.R., Thallas-Bonke, V., Pete, J., Thomas, M.C., Deemer, E.R., Bassal, S., El-Osta, A., Long, D.M., Panagiotopoulos, S., et al. (2005). Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-2 inhibition in diabetic nephropathy. *J. Am. Soc. Nephrol.* 16, 2363–2372.
- Franceschi, C., and Campisi, J. (2014). Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. *J. Gerontol. A Biol. Sci. Med. Sci.* 69 (Suppl 1), S4–S9.
- Freedman, B.I., Wuerth, J.P., Cartwright, K., Bain, R.P., Dippe, S., Hershon, K., Mooradian, A.D., and Spinowitz, B.S. (1999). Design and baseline characteristics for the aminoguanidine clinical trial in overt type 2 diabetic nephropathy (ACTION II). *Control. Clin. Trials* 20, 493–510.
- Gale, C.P., Futers, T.S., and Summers, L.K.M. (2004). Common polymorphisms in the glyoxalase-1 gene and their association with pro-thrombotic factors. *Diab. Vasc. Dis. Res.* 1, 34–39.
- Garrido, D., Rubin, T., Poidevin, M., Maroni, B., Le Rouzic, A., Parvy, J.-P., and Montagne, J. (2015). Fatty acid synthase cooperates with glyoxalase 1 to protect against sugar toxicity. *PLoS Genet.* 11, e1004995.
- Giacco, F., Du, X., D'Agati, V.D., Milne, R., Sui, G., Geoffron, M., and Brownlee, M. (2014). Knockdown of glyoxalase 1 mimics diabetic nephropathy in nondiabetic mice. *Diabetes* 63, 291–299.
- Gnerer, J.P., Kreber, R.A., and Ganetzky, B. (2006). Wasted away, a *Drosophila* mutation in triosephosphate isomerase, causes paralysis, neurodegeneration, and early death. *Proc. Natl. Acad. Sci. USA* 103, 14987–14993.
- Goldberg, T., Cai, W., Peppas, M., Dardaine, V., Baliga, B.S., Uribarri, J., and Vlassara, H. (2004). Advanced glycoxidation end products in commonly consumed foods. *J. Am. Diet. Assoc.* 104, 1287–1291.
- Golegaonkar, S., Tabrez, S.S., Pandit, A., Sethurathinam, S., Jagadeeshaprasad, M.G., Bansode, S., Sampathkumar, S.-G., Kulkarni, M.J., and Mukhopadhyay, A. (2015). Rifampicin reduces advanced glycation end products and activates DAF-16 to increase lifespan in *Caenorhabditis elegans*. *Aging Cell* 14, 463–473.
- Gomes, R.A., Vicente Miranda, H., Sousa Silva, M., Graça, G., Coelho, A.V., do Nascimento Ferreira, A.E., Cordeiro, C., and Freire, A.P. (2008). Protein glycation and methylglyoxal metabolism in yeast: finding peptide needles in protein haystacks. *FEMS Yeast Res.* 8, 174–181.
- Guerrero, E., Vasudevaraju, P., Hegde, M.L., Britton, G.B., and Rao, K.S. (2013). Recent advances in α -synuclein functions, advanced glycation, and toxicity: implications for Parkinson's disease. *Mol. Neurobiol.* 47, 525–536.
- Gugliucci, A. (2005). Alternative antiglycation mechanisms: are spermine and fructosamine-3-kinase part of a carbonyl damage control pathway? *Med. Hypotheses* 64, 770–777.

- Gugliucci, A. (2009). "Blinding" of AMP-dependent kinase by methylglyoxal: a mechanism that allows perpetuation of hepatic insulin resistance? *Med. Hypotheses* 73, 921–924.
- Gugliucci, A. (2016). Fructose surges damage hepatic adenosyl-monophosphate-dependent kinase and lead to increased lipogenesis and hepatic insulin resistance. *Med. Hypotheses* 93, 87–92.
- Gugliucci, A. (2017). Formation of Fructose-Mediated Advanced Glycation End Products and Their Roles in Metabolic and Inflammatory Diseases. *Adv. Nutr.* 8, 54–62.
- Gugliucci, A., and Bendayan, M. (1995). Reaction of advanced glycation end-products with renal tissue from normal and streptozotocin-induced diabetic rats: an ultrastructural study using colloidal gold cytochemistry. *J Histochem Cytochem* 43, 591–600.
- Gugliucci, A., and Bendayan, M. (1996). Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. *Diabetologia* 39, 149–160.
- Gugliucci, A., and Menini, T. (2017). Advanced Glycation endproducts and aging. In *Mechanisms Linking Aging, Diseases and Biological Age Estimation*, S.C. Zapico, ed. (CRC Press), pp. 68–79.
- Hammes, H.P., Alt, A., Niwa, T., Clausen, J.T., Bretzel, R.G., Brownlee, M., and Schleicher, E.D. (1999). Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. *Diabetologia* 42, 728–736.
- Henning, C., Liehr, K., Girndt, M., Ulrich, C., and Glomb, M.A. (2014). Extending the spectrum of α -dicarbonyl compounds in vivo. *J. Biol. Chem.* 289, 28676–28688.
- Hipkiss, A.R., Cartwright, S.P., Bromley, C., Gross, S.R., and Bill, R.M. (2013). Carnosine: can understanding its actions on energy metabolism and protein homeostasis inform its therapeutic potential? *Chem. Cent. J.* 7, 38.
- Im, J.Y., Lee, K.W., Woo, J.M., Junn, E., and Mouradian, M.M. (2012). DJ-1 induces thioredoxin 1 expression through the Nrf2 pathway. *Hum. Mol. Genet.* 21, 3013–3024.
- Jack, M.M., Ryals, J.M., and Wright, D.E. (2011). Characterisation of glyoxalase I in a streptozotocin-induced mouse model of diabetes with painful and insensate neuropathy. *Diabetologia* 54, 2174–2182.
- Jaramillo, R., Shuck, S.C., Chan, Y.S., Liu, X., Bates, S.E., Lim, P.P., Tamae, D., Lacoste, S., O'Connor, T.R., and Termini, J. (2017). DNA Advanced Glycation End Products (DNA-AGEs) Are Elevated in Urine and Tissue in an Animal Model of Type 2 Diabetes. *Chem. Res. Toxicol.* 30, 689–698.
- Jiang, T., Huang, Z., Lin, Y., Zhang, Z., Fang, D., and Zhang, D.D. (2010). The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. *Diabetes* 59, 850–860.
- Kalousová, M., Jáchymová, M., Mestek, O., Hodková, M., Kazderová, M., Tesar, V., and Zima, T. (2007). Receptor for advanced glycation end products-soluble form and gene polymorphisms in chronic haemodialysis patients. *Nephrol. Dial. Transplant.* 22, 2020–2026.
- Kalousová, M., Germanová, A., Jáchymová, M., Mestek, O., Tesar, V., and Zima, T. (2008). A419C (E111A) polymorphism of the glyoxalase I gene and vascular complications in chronic hemodialysis patients (In *Annals of the New York Academy of Sciences*), pp. 268–271.
- Kiefer, A.S., Fleming, T., Eckert, G.J., Poindexter, B.B., Nawroth, P.P., and Yoder, M.C. (2014). Methylglyoxal concentrations differ in standard and washed neonatal packed red blood cells. *Pediatr. Res.* 75, 409–414.
- King, A.J.F. (2012). The use of animal models in diabetes research. *Br. J. Pharmacol.* 166, 877–894.
- Ko, S.-Y., Lin, Y.-P., Lin, Y.-S., and Chang, S.-S. (2010). Advanced glycation end products enhance amyloid precursor protein expression by inducing reactive oxygen species. *Free Radic. Biol. Med.* 49, 474–480.
- Koschinsky, T., He, C.-J., Mitsuhashi, T., Bucala, R., Liu, C., Buenting, C., Heitmann, K., and Vlassara, H. (1997). Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. *Proc. Natl. Acad. Sci. USA* 94, 6474–6479.
- Kuhla, B., Boeck, K., Schmidt, A., Ogunlade, V., Arendt, T., Münch, G., and Lüth, H.J. (2007). Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer's disease brains. *Neurobiol. Aging* 28, 29–41.
- Lange, J.N., Wood, K.D., Knight, J., Assimos, D.G., and Holmes, R.P. (2012). Glyoxal formation and its role in endogenous oxalate synthesis. *Adv. Urol.* 2012, 819202.
- Ledesma, M.D., Bonay, P., Colaço, C., and Avila, J. (1994). Analysis of microtubule-associated protein tau glycation in paired helical filaments. *J. Biol. Chem.* 269, 21614–21619.
- Lee, J.-Y., Song, J., Kwon, K., Jang, S., Kim, C., Baek, K., Kim, J., and Park, C. (2012). Human DJ-1 and its homologs are novel glyoxalases. *Hum. Mol. Genet.* 21, 3215–3225.
- Lee, J.-Y., Kim, C., Kim, J., and Park, C. (2013). DJR-1.2 of *Caenorhabditis elegans* is induced by DAF-16 in the dauer state. *Gene* 524, 373–376.
- Leonardis, D., Basta, G., Mallamaci, F., Cutrupi, S., Pizzini, P., Tripepi, R., Tripepi, G., De Caterina, R., and Zoccali, C. (2012). Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD). *Nutr. Metab. Cardiovasc. Dis.* 22, 748–755.
- Li, B., Liu, S., Miao, L., and Cai, L. (2012). Prevention of diabetic complications by activation of Nrf2: diabetic cardiomyopathy and nephropathy. *Exp. Diabetes Res.* 2012, 216512.
- Li, X.-H., Du, L.-L., Cheng, X.-S., Jiang, X., Zhang, Y., Lv, B.-L., Liu, R., Wang, J.-Z., and Zhou, X.-W. (2013). Glycation exacerbates the neuronal toxicity of β -amyloid. *Cell Death Dis.* 4, e673.
- Li, X., Song, D., and Leng, S.X. (2015). Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment. *Clin. Interv. Aging* 10, 549–560.
- Lo, T.W.C., Westwood, M.E., McLellan, A.C., Selwood, T., and Thornalley, P.J. (1994). Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha-acetylglycine, N alpha-acetylcysteine, and N alpha-acetyllysine, and bovine serum albumin. *J. Biol. Chem.* 269, 32299–32305.
- López-Otín, C., Blasco, M.A., Partridge, L., Serrano, M., and Kroemer, G. (2013). The hallmarks of aging. *Cell* 153, 1194–1217.
- Lüth, H.J., Ogunlade, V., Kuhla, B., Kientsch-Engel, R., Stahl, P., Webster, J., Arendt, T., and Münch, G. (2005). Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains. *Cereb. Cortex* 15, 211–220.
- Lv, X., Lv, G.H., Dai, G.Y., Sun, H.M., and Xu, H.Q. (2016). Food-advanced glycation end products aggravate the diabetic vascular complications via modulating the AGEs/RAGE pathway. *Chin. J. Nat. Med.* 14, 844–855.
- Ma, H., Li, S.Y., Xu, P., Babcock, S.A., Dolence, E.K., Brownlee, M., Li, J., and Ren, J. (2009). Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) up-regulation contribute to the onset of diabetic cardiomyopathy. *J. Cell. Mol. Med.* 13 (8B), 1751–1764.
- Maillard, L.C. (1912). Action des Acides Aminés sur les Sucres; Formation des Mélanoidines par Voie Méthodique. *Comptes Rendus de l'Académie des Sciences*, 66–68.
- Makita, Z., Bucala, R., Rayfield, E.J., Friedman, E.A., Kaufman, A.M., Korbet, S.M., Barth, R.H., Winston, J.A., Fuh, H., Manogue, K.R., et al. (1994). Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. *Lancet* 343, 1519–1522.
- McIllduff, C.E., and Rutkove, S.B. (2011). Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy. *Ther. Clin. Risk Manag.* 7, 377–385.
- Mendler, M., Schlotterer, A., Ibrahim, Y., Kukudov, G., Fleming, T., Bierhaus, A., Riedinger, C., Schwenger, V., Herzig, S., Hecker, M., et al. (2015). daf-16/FOXO and glod-4/glyoxalase-1 are required for the life-prolonging effect of human insulin under high glucose conditions in *Caenorhabditis elegans*. *Diabetologia* 58, 393–401.
- Miyata, T., Hori, O., Zhang, J., Yan, S.D., Ferran, L., Iida, Y., and Schmidt, A.M. (1996). The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. *J. Clin. Invest.* 98, 1088–1094.
- Monnier, V.M. (1989). Toward a Maillard reaction theory of aging. *Prog. Clin. Biol. Res.* 304, 1–22.

- Monnier, V.M., and Taniguchi, N. (2016). Advanced glycation in diabetes, aging and age-related diseases: editorial and dedication. *Glycoconj. J.* 33, 483–486.
- Monnier, V.M., Stevens, V.J., and Cerami, A. (1981). Maillard reactions involving proteins and carbohydrates in vivo: relevance to diabetes mellitus and aging. *Prog. Food Nutr. Sci.* 5, 315–327.
- Monnier, V.M., Kohn, R.R., and Cerami, A. (1984). Accelerated age-related browning of human collagen in diabetes mellitus. *Proc. Natl. Acad. Sci. USA* 81, 583–587.
- Monnier, V.M., Sell, D.R., Abdul-Karim, F.W., and Emancipator, S.N. (1988). Collagen browning and cross-linking are increased in chronic experimental hyperglycemia. Relevance to diabetes and aging. *Diabetes* 37, 867–872.
- Monnier, V.M., Sell, D.R., and Genuth, S. (2005). Glycation products as markers and predictors of the progression of diabetic complications (In *Annals of the New York Academy of Sciences*), pp. 567–581.
- Monnier, V.M., Sun, W., Sell, D.R., Fan, X., Nemet, I., and Genuth, S. (2014). Glucosepane: a poorly understood advanced glycation end product of growing importance for diabetes and its complications. *Clin. Chem. Lab. Med.* 52, 21–32.
- Monnier, V.M., Sun, W., Gao, X., Sell, D.R., Cleary, P.A., Lachin, J.M., and Genuth, S.; DCCT/EDIC Research Group (2015). Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes. *Cardiovasc. Diabetol.* 14, 118.
- Morcos, M., Du, X., Pfisterer, F., Hutter, H., Sayed, A.A., Thornalley, P., Ahmed, N., Baynes, J., Thorpe, S., Kukudov, G., et al. (2008). Glyoxalase-1 prevents mitochondrial protein modification and enhances lifespan in *Caenorhabditis elegans*. *Aging Cell* 7, 260–269.
- Münch, G., Lüth, H.J., Wong, A., Arendt, T., Hirsch, E., Ravid, R., and Riederer, P. (2000). Crosslinking of alpha-synuclein by advanced glycation endproducts—an early pathophysiological step in Lewy body formation? *J. Chem. Neuroanat.* 20, 253–257.
- Münch, G., Westcott, B., Menini, T., and Gugliucci, A. (2012). Advanced glycation endproducts and their pathogenic roles in neurological disorders. *Amino Acids* 42, 1221–1236.
- Nakashima, A., Carrero, J.J., Qureshi, A.R., Miyamoto, T., Anderstam, B., Bárány, P., Heimbürger, O., Stenvinkel, P., and Lindholm, B. (2010). Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. *Clin. J. Am. Soc. Nephrol.* 5, 2213–2219.
- Nemet, I., Strauch, C.M., and Monnier, V.M. (2011). Favored and disfavored pathways of protein crosslinking by glucose: glucose lysine dimer (GLUCOLD) and crossline versus glucosepane. *Amino Acids* 40, 167–181.
- Nowotny, K., Jung, T., Grune, T., and Höhn, A. (2014). Reprint of “accumulation of modified proteins and aggregate formation in aging”. *Exp. Gerontol.* 59, 3–12.
- Oldfield, M.D., Bach, L.A., Forbes, J.M., Nikolic-Paterson, D., McRobert, A., Thallas, V., Atkins, R.C., Osicka, T., Jerums, G., and Cooper, M.E. (2001). Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). *J. Clin. Invest.* 108, 1853–1863.
- Peculis, R., Konrade, I., Skapare, E., Fridmanis, D., Nikitina-Zake, L., Lejnicks, A., Pirags, V., Dambrova, M., and Klovins, J. (2013). Identification of glyoxalase 1 polymorphisms associated with enzyme activity. *Gene* 515, 140–143.
- Peppas, M., and Vlassara, H. (2005). Advanced glycation end products and diabetic complications: a general overview. *Hormones (Athens)* 4, 28–37.
- Pfaff, D.H., Fleming, T., Nawroth, P., and Telemann, A.A. (2017). Evidence Against a Role for the Parkinsonism-associated Protein DJ-1 in Methylglyoxal Detoxification. *J. Biol. Chem.* 292, 685–690.
- Piperi, C., Adamopoulos, C., Dalagiorgou, G., Diamanti-Kandarakis, E., and Papavassiliou, A.G. (2012). Crosstalk between advanced glycation and endoplasmic reticulum stress: emerging therapeutic targeting for metabolic diseases. *J. Clin. Endocrinol. Metab.* 97, 2231–2242.
- Rabbani, N., and Thornalley, P.J. (2009). Quantitation of markers of protein damage by glycation, oxidation, and nitration in peritoneal dialysis. *Perit. Dial. Int.* 29 (Suppl 2), S51–S56.
- Rabbani, N., and Thornalley, P.J. (2014). Measurement of methylglyoxal by stable isotopic dilution analysis LC-MS/MS with corroborative prediction in physiological samples. *Nat. Protoc.* 9, 1969–1979.
- Rabbani, N., and Thornalley, P.J. (2015a). Hidden complexities in the measurement of fructosyl-lysine and advanced glycation end products for risk prediction of vascular complications of diabetes. *Diabetes* 64, 9–11.
- Rabbani, N., and Thornalley, P.J. (2015b). Dicarbonyl stress in cell and tissue dysfunction contributing to ageing and disease. *Biochem. Biophys. Res. Commun.* 458, 221–226.
- Rabbani, N., and Thornalley, P.J. (2018a). Advanced glycation end products in the pathogenesis of chronic kidney disease. *Kidney Int.* 93, 803–813.
- Rabbani, N., and Thornalley, P.J. (2018b). Glyoxalase 1 Modulation in Obesity and Diabetes. *Antioxid. Redox Signal.* Published online January 2, 2018. <https://doi.org/10.1089/ars.2017.7424>.
- Rabbani, N., Sebekova, K., Sebekova, K., Jr., Heidland, A., and Thornalley, P.J. (2007). Accumulation of free adduct glycation, oxidation, and nitration products follows acute loss of renal function. *Kidney Int.* 72, 1113–1121.
- Rahbar, S., Blumenfeld, O., and Ranney, H.M. (1969). Studies of an unusual hemoglobin in patients with diabetes mellitus. *Biochem. Biophys. Res. Commun.* 36, 838–843.
- Ramasamy, R., Yan, S.F., and Schmidt, A.M. (2011). Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. *Ann. N Y Acad. Sci.* 1243, 88–102.
- Raposeiras-Roubín, S., Rodiño-Janeiro, B.K., Grigorian-Shamagian, L., Moure-González, M., Seoane-Blanco, A., Varela-Román, A., Alvarez, E., and González-Juanatey, J.R. (2010). Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: New Roles for Soluble RAGE. *Eur. J. Heart Fail.* 12, 1092–1100.
- Ravichandran, M., Priebe, S., Grigolon, G., Rozanov, L., Groth, M., Laube, B., Guthke, R., Platzer, M., Zarse, K., and Ristow, M. (2018). Impairing L-Threonine Catabolism Promotes Healthspan through Methylglyoxal-Mediated Proteohormesis. *Cell Metab.* 27, 914–925.e5.
- Richarme, G., and Dairou, J. (2017). Parkinsonism-associated protein DJ-1 is a bona fide deglycase. *Biochem. Biophys. Res. Commun.* 483, 387–391.
- Richarme, G., Mihoub, M., Dairou, J., Bui, L.C., Leger, T., and Lamouri, A. (2015). Parkinsonism-associated protein DJ-1/Park7 is a major protein deglycase that repairs methylglyoxal- and glyoxal-glycated cysteine, arginine, and lysine residues. *J. Biol. Chem.* 290, 1885–1897.
- Richarme, G., Liu, C., Mihoub, M., Abdallah, J., Leger, T., Joly, N., Liebart, J.-C., Jurkunas, U.V., Nadal, M., Boulouc, P., et al. (2017). Guanine glycation repair by DJ-1/Park7 and its bacterial homologs. *Science* 357, 208–211.
- Rodríguez-Ayala, E., Anderstam, B., Suliman, M.E., Seeburger, A., Heimbürger, O., Lindholm, B., and Stenvinkel, P. (2005). Enhanced RAGE-mediated NFKappaB stimulation in inflamed hemodialysis patients. *Atherosclerosis* 180, 333–340.
- Sayeg, W.N., Knight Iii, P.R., Guo, W.A., Mullan, B., Ohtake, P.J., Davidson, B.A., Khan, A., Baker, R.D., and Baker, S.S. (2016). Advanced Glycation End Products Induce Obesity and Hepatosteatosis in CD-1 Wild-Type Mice. *BioMed Res. Int.* 2016, 7867852.
- Schlotterer, A., Kukudov, G., Bozorgmehr, F., Hutter, H., Du, X., Oikonomou, D., Ibrahim, Y., Pfisterer, F., Rabbani, N., Thornalley, P., et al. (2009). *C. elegans* as model for the study of high glucose-mediated life span reduction. *Diabetes* 58, 2450–2456.
- Schmidt, A.M., and Stern, D. (2000). Atherosclerosis and diabetes: the RAGE connection. *Curr. Atheroscler. Rep.* 2, 430–436.
- Schmidt, A.M., Hori, O., Chen, J.X., Li, J.F., Crandall, J., Zhang, J., Cao, R., Yan, S.D., Brett, J., and Stern, D. (1995). Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. *J. Clin. Invest.* 96, 1395–1403.
- Schmidt, A.M., Hori, O., Cao, R., Yan, S.D., Brett, J., Wautier, J.L., Ogawa, S., Kuwabara, K., Matsumoto, M., and Stern, D. (1996). RAGE: a novel cellular

- receptor for advanced glycation end products. *Diabetes* 45 (Suppl 3), S77–S80.
- Sell, D.R., and Monnier, V.M. (1989). Structure elucidation of a senescence cross-link from human extracellular matrix. Implication of pentoses in the aging process. *J. Biol. Chem.* 264, 21597–21602.
- Sell, D.R., Lapolla, A., Odetti, P., Fogarty, J., and Monnier, V.M. (1992). Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. *Diabetes* 41, 1286–1292.
- Sell, D.R., Lane, M.A., Johnson, W.A., Masoro, E.J., Mock, O.B., Reiser, K.M., Fogarty, J.F., Cutler, R.G., Ingram, D.K., Roth, G.S., and Monnier, V.M. (1996). Longevity and the genetic determination of collagen glycoxidation kinetics in mammalian senescence. *Proc. Natl. Acad. Sci. USA* 93, 485–490.
- Semba, R.D., Bandinelli, S., Sun, K., Guralnik, J.M., and Ferrucci, L. (2009). Plasma carboxymethyl-lysine, an advanced glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling adults. *J. Am. Geriatr. Soc.* 57, 1874–1880.
- Serratos, I.N., Castellanos, P., Pastor, N., Millán-Pacheco, C., Colín-González, A.L., Rembao, D., Pérez-Montfort, R., Cabrera, N., Sánchez-García, A., Gómez, I., et al. (2016). Early expression of the receptor for advanced glycation end products in a toxic model produced by 6-hydroxydopamine in the rat striatum. *Chem. Biol. Interact.* 249, 10–18.
- Shaikh, S., and Nicholson, L.F.B. (2008). Advanced glycation end products induce in vitro cross-linking of α -synuclein and accelerate the process of intracellular inclusion body formation. *J. Neurosci. Res.* 86, 2071–2082.
- Singh, V.P., Bali, A., Singh, N., and Jaggi, A.S. (2014). Advanced glycation end products and diabetic complications. *Korean J. Physiol. Pharmacol.* 18, 1–14.
- Song, D.W., Xin, N., Xie, B.J., Li, Y.J., Meng, L.Y., Li, H.M., Schläppi, M., and Deng, Y.L. (2014). Formation of a salsolinol-like compound, the neurotoxin, 1-acetyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, in a cellular model of hyperglycemia and a rat model of diabetes. *Int. J. Mol. Med.* 33, 736–742.
- Sousa Silva, M., Gomes, R.A., Ferreira, A.E.N., Ponces Freire, A., and Cordeiro, C. (2013). The glyoxalase pathway: the first hundred years... and beyond. *Biochem. J.* 453, 1–15.
- Sveen, K.A., Dahl-Jørgensen, K., Stensaeth, K.H., Angel, K., Seljeflot, I., Sell, D.R., Monnier, V.M., and Hanssen, K.F. (2015). Glucosepane and oxidative markers in skin collagen correlate with intima media thickness and arterial stiffness in long-term type 1 diabetes. *J. Diabetes Complications* 29, 407–412.
- Szwergold, B.S., Bunker, R.D., and Loomes, K.M. (2011). The physiological substrates of fructosamine-3-kinase-related-protein (FN3KRP) are intermediates of nonenzymatic reactions between biological amines and ketose sugars (fructation products). *Med. Hypotheses* 77, 739–744.
- Tanji, N., Markowitz, G.S., Fu, C., Kislinger, T., Taguchi, A., Pischetsrieder, M., Stern, D., Schmidt, A.M., and D'Agati, V.D. (2000). Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. *J. Am. Soc. Nephrol.* 11, 1656–1666.
- Thornalley, P.J. (1990). The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. *Biochem. J.* 269, 1–11.
- Thornalley, P.J. (2003). Use of aminoguanidine (Pimgedine) to prevent the formation of advanced glycation endproducts. *Arch. Biochem. Biophys.* 419, 31–40.
- Thornalley, P.J. (2005a). Glycation free adduct accumulation in renal disease: the new AGE. *Pediatr. Nephrol.* 20, 1515–1522.
- Thornalley, P.J. (2005b). Measurement of protein glycation, glycated peptides, and glycation free adducts. *Perit. Dial. Int.* 25, 522–533.
- Thornalley, P.J. (2006). Advanced glycation end products in renal failure. *J. Ren. Nutr.* 16, 178–184.
- Thornalley, P.J., and Rabbani, N. (2009). Highlights and hotspots of protein glycation in end-stage renal disease. *Semin. Dial.* 22, 400–404.
- Thornalley, P.J., Battah, S., Ahmed, N., Karachalias, N., Agalou, S., Babaei-Jadidi, R., and Dawnay, A. (2003). Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. *Biochem. J.* 375, 581–592.
- Thorpe, S.R., and Baynes, J.W. (2003). Maillard reaction products in tissue proteins: new products and new perspectives. *Amino Acids* 25, 275–281.
- Trojanowski, J.Q., Goedert, M., Iwatsubo, T., and Lee, V.M.Y. (1998). Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. *Cell Death Differ.* 5, 832–837.
- Tsantoulas, C., Láinez, S., Wong, S., Mehta, I., Vilar, B., and McNaughton, P.A. (2017). Hyperpolarization-activated cyclic nucleotide-gated 2 (HCN2) ion channels drive pain in mouse models of diabetic neuropathy. *Sci. Transl. Med.* 9, m6072.
- Uchiki, T., Weikel, K.A., Jiao, W., Shang, F., Caceres, A., Pawlak, D., Handa, J.T., Brownlee, M., Nagaraj, R., and Taylor, A. (2012). Glycation-altered proteolysis as a pathobiologic mechanism that links dietary glycemic index, aging, and age-related disease (in nondiabetics). *Aging Cell* 11, 1–13.
- Uribarri, J., Peppas, M., Cai, W., Goldberg, T., Lu, M., Baliga, S., Vassalotti, J.A., and Vlassara, H. (2003a). Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. *Am. J. Kidney Dis.* 42, 532–538.
- Uribarri, J., Peppas, M., Cai, W., Goldberg, T., Lu, M., He, C., and Vlassara, H. (2003b). Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. *J. Am. Soc. Nephrol.* 14, 728–731.
- Uribarri, J., del Castillo, M.D., de la Maza, M.P., Filip, R., Gugliucci, A., Luevano-Contreras, C., Macías-Cervantes, M.H., Markowicz Bastos, D.H., Medrano, A., Menini, T., et al. (2015). Dietary advanced glycation end products and their role in health and disease. *Adv. Nutr.* 6, 461–473.
- Van Schaftingen, E., Delpierre, G., Collard, F., Fortpied, J., Gemayel, R., Wiame, E., and Veiga-da-Cunha, M. (2007). Fructosamine 3-kinase and other enzymes involved in protein deglycation. *Adv. Enzyme Regul.* 47, 261–269.
- Vander Jagt, D.L., Robinson, B., Taylor, K.K., and Hunsaker, L.A. (1992). Reduction of trioses by NADPH-dependent aldo-keto reductases. Aldose reductase, methylglyoxal, and diabetic complications. *J. Biol. Chem.* 267, 4364–4369.
- Vashishth, D. (2009). Advanced glycation end-products and bone fractures. *IBMS boneKey* 6, 268–278.
- Vazzana, N., Santilli, F., Cucurullo, C., and Davi, G. (2009). Soluble forms of RAGE in internal medicine. *Intern. Emerg. Med.* 4, 389–401.
- Vicente Miranda, H., Gomes, M.A., Branco-Santos, J., Breda, C., Lázaro, D.F., Lopes, L.V., Herrera, F., Giorgini, F., and Outeiro, T.F. (2016). Glycation potentiates neurodegeneration in models of Huntington's disease. *Sci. Rep.* 6, 36798.
- Vicente Miranda, H., Szego, É.M., Oliveira, L.M.A., Breda, C., Darendelioglu, E., de Oliveira, R.M., Ferreira, D.G., Gomes, M.A., Rott, R., Oliveira, M., et al. (2017). Glycation potentiates α -synuclein-associated neurodegeneration in synucleinopathies. *Brain* 140, 1399–1419.
- Vitek, M.P., Bhattacharya, K., Glendening, J.M., Stopa, E., Vlassara, H., Bucala, R., Manogue, K., and Cerami, A. (1994). Advanced glycation end products contribute to amyloidosis in Alzheimer disease. *Proc. Natl. Acad. Sci. USA* 91, 4766–4770.
- Vlassara, H. (1994). Serum advanced glycosylation end products: a new class of uremic toxins? *Blood Purif.* 12, 54–59.
- Vlassara, H., and Uribarri, J. (2014). Advanced glycation end products (AGE) and diabetes: cause, effect, or both? *Curr. Diab. Rep.* 14, 453.
- Vlassara, H., Fuh, H., Makita, Z., Krunkkrai, S., Cerami, A., and Bucala, R. (1992). Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. *Proc. Natl. Acad. Sci. USA* 89, 12043–12047.
- Woltjer, R.L., Maezawa, I., Ou, J.J., Montine, K.S., and Montine, T.J. (2003). Advanced glycation endproduct precursor alters intracellular amyloid-beta/A beta PP carboxy-terminal fragment aggregation and cytotoxicity. *J. Alzheimers Dis.* 5, 467–476.
- Wu, J.C., Li, X.H., Peng, Y.D., Wang, J.B., Tang, J.F., and Wang, Y.F. (2011). Association of two glyoxalase I gene polymorphisms with nephropathy and retinopathy in Type 2 diabetes. *J. Endocrinol. Invest.* 34, e343–e348.

- Xie, B., Lin, F., Ullah, K., Peng, L., Ding, W., Dai, R., Qing, H., and Deng, Y. (2015). A newly discovered neurotoxin ADTIQ associated with hyperglycemia and Parkinson's disease. *Biochem. Biophys. Res. Commun.* *459*, 361–366.
- Xue, M., Rabhani, N., Momiji, H., Imbasi, P., Anwar, M.M., Kitteringham, N., Park, B.K., Souma, T., Moriguchi, T., Yamamoto, M., and Thornalley, P.J. (2012). Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycation. *Biochem. J.* *443*, 213–222.
- Yamagishi, S. (2011). Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. *Curr. Drug Targets* *12*, 2096–2102.
- Yamagishi, S., Nakamura, K., Matsui, T., Inagaki, Y., Takenaka, K., Jinnouchi, Y., Yoshida, Y., Matsuura, T., Narama, I., Motomiya, Y., et al. (2006). Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. *J. Biol. Chem.* *281*, 20213–20220.
- Yan, S.F., Ramasamy, R., and Schmidt, A.M. (2010a). The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature. *Circ. Res.* *106*, 842–853.
- Yan, S.F., Ramasamy, R., and Schmidt, A.M. (2010b). Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. *Biochem. Pharmacol.* *79*, 1379–1386.
- Zemva, J., Fink, C.A., Fleming, T.H., Schmidt, L., Loft, A., Herzig, S., Knieß, R.A., Mayer, M., Bukau, B., Nawroth, P.P., and Tyedmers, J. (2017). Hormesis enables cells to handle accumulating toxic metabolites during increased energy flux. *Redox Biol.* *13*, 674–686.
- Zheng, F., Cai, W., Mitsuhashi, T., and Vlassara, H. (2001). Lysozyme enhances renal excretion of advanced glycation endproducts in vivo and suppresses adverse age-mediated cellular effects in vitro: a potential AGE sequestration therapy for diabetic nephropathy? *Mol. Med.* *7*, 737–747.
- Zheng, W.-H., Bastianetto, S., Mennicken, F., Ma, W., and Kar, S. (2002). Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. *Neuroscience* *115*, 201–211.
- Zheng, H., Whitman, S.A., Wu, W., Wondrak, G.T., Wong, P.K., Fang, D., and Zhang, D.D. (2011). Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. *Diabetes* *60*, 3055–3066.
- Zhou, Z., Tang, Y., Jin, X., Chen, C., Lu, Y., Liu, L., and Shen, C. (2016). Metformin Inhibits Advanced Glycation End Products-Induced Inflammatory Response in Murine Macrophages Partly through AMPK Activation and RAGE/NF κ B Pathway Suppression. *J. Diabetes Res.* *2016*, 4847812.
- Ziegler, D., Reljanovic, M., Mehnert, H., and Gries, F.A. (1999). Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. *Exp. Clin. Endocrinol. Diabetes* *107*, 421–430.